Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

Columbia University

Status and phase: Terminated; Phase 4

Conditions: Cerebral Palsy

Treatments: Drug: Amantadine Hydrochloride

Study type: Interventional

Funder types: Other

Identifiers

NCT04273737

AAAS1907

Details and patient eligibility

About

Cerebral palsy (CP) is a common childhood-onset disability associated with motor and cognitive impairments, however most research is focused on motor outcomes. The aim of this study is to determine the effects of Amantadine, a dopaminergic agonist, on cognitive function in adolescents and adults with CP.

Full description

CP is a heterogeneous condition due to injury to the developing brain. It is a condition that is often marked by both cognitive and motor disorders as well as increased prevalence of depression and anxiety. While most studies have focused on improving motor dysfunction, fewer have investigated cognitive impairments associated with CP. Dedicating a study to research the pharmacotherapeutic effect of Amantadine on cognitive function in adolescents and adults with cerebral palsy fills an important gap in development of a potential innovative treatment for cognitive deficits. The investigators hope to determine the effects of Amantadine on cognitive function in adolescents and adults with CP. The investigators will also evaluate secondary goals of improving gross and fine motor skills and mood.

Enrollment: 11 patients

Sex: All

Ages: 12 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Cerebral Palsy

Exclusion criteria

• Currently pregnant
• Unstable seizure condition
• Currently taking methadone
• Currently taking other dopamine agonists
• Currently taking anti-psychotic medication
• Previously taken amantadine
• Diagnosed with Chronic Kidney Disease (CKD)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

Amantadine

Experimental group

Description:

Daily regimen of amantadine hydrochloride tablets for 6 weeks: dosing of 5mg/kg divided by two daily doses (max daily dose of 300 mg)

Treatment:

Drug: Amantadine Hydrochloride